Dan Gliddon

Dan Gliddon has been Chief Operating Officer of Forcefield Therapeutics since 2021. Dan is a virtual R&D model managed by biologics development specialist with over 15 years of biopharmaceutical discovery and development experience in pharma, CRO and biotech. He is a former member of the executive leadership team at F-star Therapeutics, leading the clinical translation of their innovative bispecific antibodies, and supporting the company’s corporate development and Nasdaq listing.